PMID- 32323156
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 11
IP  - Suppl 1
DP  - 2020 Jun
TI  - Latest Evidence on Sulfonylureas: What's New?
PG  - 15-22
LID - 10.1007/s13300-020-00812-2 [doi]
AB  - This review addresses the question of the cardiovascular (CV) safety of 
      sulfonylureas (SUs) in patients with type 2 diabetes mellitus (T2DM) when 
      directly tested against comparator agents in CV outcome trials. Presented at a 
      recent symposium entitled "SUs in the treatment of T2DM: a fresh look and new 
      insights" held on Wednesday September 18, 2019 during the 55th Annual Meeting of 
      the European Association for the Study of Diabetes (EASD) in Barcelona Spain, 
      this review discusses the initial evidence that sparked concerns over the CV 
      safety of SUs as well as more recent findings from large studies of SUs (i.e. 
      ADVANCE, TOSCA.IT and CAROLINA trials), highlighting the differences in CV and 
      hypoglycaemia risks among the various SUs. Finally, the impact of glycaemic 
      control on CV outcomes is also discussed, where the data suggest that the recent 
      positive CV outcomes with some antihyperglycaemic agents may have been driven in 
      part by improved glycaemic control.
FAU - Leiter, Lawrence A
AU  - Leiter LA
AD  - Division of Endocrinology and Metabolism, Li Ka Shing Knowledge Institute, St 
      Michael's Hospital, University of Toronto, Toronto, Canada. 
      Lawrence.Leiter@unityhealth.to.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200422
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC7261305
OTO - NOTNLM
OT  - Cardiovascular outcomes
OT  - Sulfonylureas
OT  - Type 2 diabetes mellitus
EDAT- 2020/04/24 06:00
MHDA- 2020/04/24 06:01
PMCR- 2020/04/22
CRDT- 2020/04/24 06:00
PHST- 2020/01/29 00:00 [received]
PHST- 2020/04/24 06:00 [pubmed]
PHST- 2020/04/24 06:01 [medline]
PHST- 2020/04/24 06:00 [entrez]
PHST- 2020/04/22 00:00 [pmc-release]
AID - 10.1007/s13300-020-00812-2 [pii]
AID - 812 [pii]
AID - 10.1007/s13300-020-00812-2 [doi]
PST - ppublish
SO  - Diabetes Ther. 2020 Jun;11(Suppl 1):15-22. doi: 10.1007/s13300-020-00812-2. Epub 
      2020 Apr 22.